Fouzia Laghrissi-Thodes
Directeur/Bestuurslid bij MINERVA NEUROSCIENCES, INC.
Vermogen: - $ op 31-05-2024
Oorsprong van het eerstegraads netwerk van Fouzia Laghrissi-Thodes
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 23 | |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology DalCor Pharmaceuticals Canada, Inc. develops precision treatments for cardiovascular diseases. It offers dalcetrapib, a cholesterol ester transfer protein (CETP) inhibitor, as a potential targeted treatment to address the residual cardiovascular risk in patients carrying a specific ADCY9 genetic profile. The company was founded by Andr? Roger Desmarais and is headquartered in Montreal, Canada.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation.
5
| Holding Company | Biotechnology | 5 |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Smart Immune SAS is a clinical-stage biotechnology company based in Paris, France. Smart Immune is developing Protcell, a thymus-empowered T cell progenitor therapy platform to re-arm the immune system against cancer and infection, enabling next-generation allogeneic T cell therapies for all. The French company aims to improve outcomes for patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies. Smart Immune has ongoing collaborations with leading institutions in the EU and the US. Smart101 is already in phase I/II clinical trials in the EU and the US, looking at the acceleration of complete immune recovery in patients fighting cancer and infection and undergoing allogeneic hematopoietic stem cell transplantation. Smart Immune is also developing therapies using gene-modified T cell progenitors through its Protcell platform to provide targeted treatments against cancer, like persistent off-the-shelf CAR T cells. The company is headquartered at Biotech Santé. The company was founded in 2017 by Karine Rossignol, Marina Cavazzana, Isabelle André, with Karine Rossignol as the CEO since 2017.
2
| Holding Company | Biotechnology | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Fouzia Laghrissi-Thodes via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Comptroller/Controller/Auditor Director/Board Member | |
Revitas, Inc.
Revitas, Inc. Packaged SoftwareTechnology Services Revitas, Inc. engages in the delivering integrated solutions for contract, revenue and compliance management. The company was founded in 1989 and is headquartered in Philadelphia, PA. | Packaged Software | Director/Board Member | |
ViaCell, Inc.
ViaCell, Inc. Medical SpecialtiesHealth Technology ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Chief Executive Officer | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
BodyMedia, Inc.
BodyMedia, Inc. Specialty StoresRetail Trade Body Media, Inc. develops, markets, and sells body monitoring products and applications. It offers wearable body monitors that record and transmit physiological data utilized in observing health and wellness conditions particularly weight management. The company was founded by John Stivoric in 1999 and is headquartered in Pittsburgh, PA. | Specialty Stores | Director/Board Member | |
University of Notre Dame | College/University | Undergraduate Degree Corporate Officer/Principal | |
AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
IPSEN | Pharmaceuticals: Major | Director/Board Member | |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
NormOxys, Inc.
NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Pharmaceuticals: Major | Director/Board Member | |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Investment Managers | Private Equity Analyst Private Equity Investor | |
BNP Paribas Fortis Private Equity Belgium NV
BNP Paribas Fortis Private Equity Belgium NV Investment ManagersFinance BNP Paribas Fortis Private Equity Belgium NV is a Private Equity/Venture Capital firm, a subsidiary of BNP Paribas Fortis SA/NV founded in 1981. BNP Paribas Fortis Private Equity Belgium NV is headquartered in Brussels. | Investment Managers | Private Equity Investor | |
UPMC Health System
UPMC Health System Hospital/Nursing ManagementHealth Services Part of UPMC Western Maryland Corp., UPMC Health System owns and operates 15 tertiary, specialty care, and community hospitals, and 24 surgical centers. The company is based in Pittsburgh, PA. | Hospital/Nursing Management | Chief Tech/Sci/R&D Officer | |
Boston College | College/University | Undergraduate Degree Undergraduate Degree | |
Yale University | College/University | Doctorate Degree | |
Invest.BW SA
Invest.BW SA Investment ManagersFinance Societe de Developpement et de Participation du Brabant Wallon SA (Invest.BW) is a private equity and venture capital firm founded in 1987. Invest.BW SA is headquartered in Louvain-la-Neuve. | Investment Managers | Private Equity Investor | |
GreenWatt SA
GreenWatt SA Electric UtilitiesUtilities GreenWatt SA designs and installs on-site bio-methanization plants. It engages in the provision of renewable energy and recycling solutions for waste bio-methanization cogeneration. The company was founded by Marc-Jean Spiltoir, Patrick Alexandre Thierry Rene van den Broucke, and Therese Marie Wathelet Florence in 2004 and is headquartered in Louvain-la-Neuve, Belgium. | Electric Utilities | Director/Board Member | |
LinguaFlex, Inc.
LinguaFlex, Inc. Medical SpecialtiesHealth Technology LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA. | Medical Specialties | Director/Board Member | |
NOVOCURE LIMITED | Medical Specialties | Chairman Director/Board Member | |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
PROMETHERA Biosciences SA
PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Pharmaceuticals: Major | Director/Board Member Founder | |
Amakem NV
Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Chairman Director/Board Member | |
Mind-NRG SARL
Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Medical/Nursing Services | President Chairman Director/Board Member | |
Xenikos BV
Xenikos BV Medical SpecialtiesHealth Technology Xenikos BV focuses on the development of immunotherapies for the treatment of patients suffering from immune diseases. It is developing a combination of two toxin-loaded anti-T-cell antibodies, T-Guard, as a therapeutic tool for resetting the body's immune system in T-cell mediated diseases. The company was founded by Ypek van Oosterhout in September 2009 and is headquartered in Nijmegen, the Netherlands. | Medical Specialties | Director/Board Member | |
Harvard Business School | College/University | Masters Business Admin Masters Business Admin | |
Levicept Ltd.
Levicept Ltd. Pharmaceuticals: GenericHealth Technology Levicept Ltd. develops a biological therapy for the treatment of osteoarthritis and chronic pain. Its treatments include p75NTR-Fc and LEVI-04. The company was founded by Simon Lempriere Westbrook on August 23, 2012 and is headquartered in Sandwich, the United Kingdom. | Pharmaceuticals: Generic | Director/Board Member | |
Stx Pharma Ltd. | Director/Board Member | ||
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Investment Managers | Founder Founder | |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Medical Specialties | Director/Board Member | |
Kymo Therapeutics Ltd.
Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Biotechnology | Director/Board Member | |
Mavalon Therapeutics Ltd.
Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Medical Specialties | Director/Board Member | |
UltraHuman Ltd.
UltraHuman Ltd. Miscellaneous Commercial ServicesCommercial Services UltraHuman Ltd. engages in research and experimental development on biotechnology. The company is headquartered in Sandwich, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Critical Pressure Ltd.
Critical Pressure Ltd. Pharmaceuticals: MajorHealth Technology Critical Pressure Ltd. engages in research and experimental development on biotechnology. The firm develops products to treat vascular dysfunction and shock. The company is headquartered in Babraham, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Human Antibody Factory Ltd.
Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Biotechnology | Director/Board Member | |
DalCor Pharma UK Ltd.
DalCor Pharma UK Ltd. BiotechnologyHealth Technology Founded in 2015, DalCor Pharma UK Ltd. is a subsidiary of DalCor Pharmaceuticals Canada, Inc. The company is based in Leatherhead, UK. The British company engages in research and experimental development on biotechnology. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
Kaerus Bioscience Ltd. | Director/Board Member | ||
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Pharmaceuticals: Major | Director/Board Member | |
Orexia Therapeutics Ltd.
Orexia Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Orexia Ltd. develop orally administered orexin positive modulators for the treatment of neurological diseases. The company was founded on October 5, 2018 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
SDS Therapeutics Ltd.
SDS Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services SDS Therapeutics Ltd. is a British biotechnology company founded in 2020 that provides research and development services. The company is based in Cambridge, UK. | Miscellaneous Commercial Services | Director/Board Member |
Statistieken
Internationaal
Verenigde Staten | 19 |
Verenigd Koninkrijk | 16 |
België | 6 |
Nederland | 6 |
Frankrijk | 4 |
Sectoraal
Health Technology | 29 |
Commercial Services | 6 |
Consumer Services | 5 |
Finance | 5 |
Health Services | 5 |
Operationeel
Director/Board Member | 242 |
Corporate Officer/Principal | 65 |
Independent Dir/Board Member | 52 |
Chairman | 44 |
Chief Executive Officer | 34 |
Sterkste connecties
Insiders | |
---|---|
Michèle Ollier | 40 |
Chris Buyse | 39 |
Bill Doyle | 38 |
Francesco de Rubertis | 36 |
Hans-Peter Hasler | 28 |
Paul R. Fonteyne | 25 |
Marc Beer | 25 |
Robert McNeil | 21 |
Jeryl Hilleman | 19 |
Nico Vandervelpen | 17 |
Geoff Race | 17 |
Dominique Costantini | 15 |
Jan van Heek | 15 |
Royston Glasspool | 11 |
Devin Smith | 11 |
- Beurs
- Insiders
- Fouzia Laghrissi-Thodes
- Bedrijfsconnecties